ویکی‌پدیا

واکسن کووید-۱۹

انواع واکسن کووید ۱۹
(تغییرمسیر از واکسن کووید ۱۹)

واکسن بیماری کروناویروس ۲۰۱۹ (به انگلیسی: COVID‑19 vaccine) واکسن‌هایی هستند که با هدف ایجاد ایمنی اکتسابی علیه بیماری کروناویروس ۲۰۱۹ (کووید‑۱۹) در حال طراحی، ساخت یا تولید هستند. اقداماتی که در گذشته به منظور تهیهٔ واکسن علیه بیماری‌های کروناویروسی مانند نشانگان تنفسی حاد و نشانگان تنفسی خاورمیانه انجام شد، باعث افزایش اطلاعات در مورد ساختار و عملکرد کروناویروس‌ها شده‌است. این اطلاعات به دانشمندان کمک می‌کند که با سرعتی بالاتر از حد معمول، واکسن‌هایی متعد و نوآورانه برای مقابله با کووید‑۱۹ طراحی و تولید کنند.[۱]

وضعیت مجوز استفاده از واکسن‌های کووید-۱۹ در کشورهای مختلف
  تأیید شده برای استفاده عمومی، واکسیناسیون دسته جمعی در حال انجام است
  
مجوز استفاده اضطراری (یا معادل آن) واکسیناسیون دسته جمعی در حال انجام است
  EUA granted, limited vaccination
  Approved for general use, mass vaccination planned
  EUA granted, mass vaccination planned
  EUA pending

تا ژانویهٔ ۲۰۲۱ تعداد ۶۹ واکسن پیشنهادی در مرحلهٔ کارازمایی بالینیقرار گرفت که شامل ۴۳ واکسن در فازهای ۱ و ۲ و ۲۶ واکسن در فازهای ۲ و ۳ می‌شد.[۲] در فاز ۳ چندین واکسن پیشنهادی دارای تأثیری ۹۵درصدی در جلوگیری از ابتلا به کووید-۱۹ گزارش شده‌اند. تا آوریل ۲۰۲۱ تعداد ۱۷ واکسن، حداقل از یک کشور مجوز استفاده درمانی برای تزریق و استفادهٔ عمومی را دریافت کرده‌اند. این واکسن‌ها شامل ۲ واکسن RNA (واکسن کووید-۱۹ فایزر و واکسن کووید-۱۹ مدرنا)، ۸ واکسن ویروس غیرفعال (کروناواک،) سینوفارم، کوواکسین، کووایران برکت، کووی‌واک، Minhai-Kangtai, QazVac و WIBP-CorV و بی‌بی‌آی‌بی‌پی-کروی)، ۶ واکسن ناقل ویروسی (اسپوتنیک V، اسپوتنیک لایت، جانسون اند جانسون، Convidecia و آکسفورد-آسترازنکا) و ۲ واکسن پپتیدی (EpiVacCorona و RBD-Dimer) هستند.[۳] بسیاری از کشورها اولویت دریافت واکسن را به گروه‌های جمعیتی با خطر بالا مانند افراد مسن و افراد در معرض ابتلا مانند کادر درمانی اختصاص داده‌اند.[۴] طبق آمار رسمی تا ۶ ژوئن ۲۰۲۱ حدود ۲/۱۵ میلیارد دوز واکسن در سراسر دنیا به افراد تزریق شده‌است.[۵] فایزر، مدرنا و آسترازنکا پیش‌بینی کرده‌اند که تا پایان سال ۲۰۲۱ می‌توانند ۵/۳ میلیارد دوز واکسن تولید کنند که این تعداد می‌تواند حدود ۳ میلیارد نفر را واکسینه کند. تا ماه دسامبر ۲۰۲۰ بیش از ۱۰ میلیارد دوز واکسن توسط کشورهای مختلف، پیش سفارش شد.[۶] حدود نیمی از این تعداد توسط کشورهای ثروتمندی خریداری شده‌اند که در مجموع تنها ۱۴ درصد از جمعیت دنیا را شامل می‌شوند.[۷]

تاریخچه

ویرایش

تا ماه اکتبر ۲۰۲۰، بیش از ۳۲۱ واکسن کاندید در سطح جهان در حال توسعه بودند. که ۲٫۵ برابر نسبت به آوریل آن سال بود.[۸] در نوامبر، ۵۶ واکسن کاندید در حال پژوهش بالینی بودند: ۴۱ واکسن در فاز آزمایش‌های ۱–۲ و ۱۵ تا فاز 2-3.[۸][۹][۱۰][۱۱] در نوامبر ۲۰۲۰، فایزر[۱۲] مدرنا[۱۳] دانشگاه آکسفورد (در همکاری با آسترازنکا),[۱۴][۱۵] نتایج مثبتی از تحلیل‌های آزمایش‌های مقدماتی فاز ۳ واکسن شان اعلام کردند.

سازمان جهانی بهداشت (WHO)، ائتلاف نوآوری‌های آمادگی همه‌گیری (CEPI) و بنیاد بیل و ملیندا گیتس (GF) برای این احتمال که واکسن‌های متعددی به منظور جلوگیری از از ادامه بیماری کووید-۱۹ مورد نیاز خواهد بود متعهد پول و منابع سازمانی شده‌اند.[۱۶]

در فوریه سال ۲۰۲۰، سازمان بهداشت جهانی (WHO) اعلام کرد که انتظار نمی‌رود واکسنی علیه کووید-۱۹، در مدت کمتر از ۱۸ ماه عرضه شود.[۱۷] نظر ائتلاف برای نوآوری‌های آمادگی اپیدمی (CEPI) که برای سرمایه‌گذاری سریع و توسعه کاندیداهای واکسن، یک صندوق ۲ دلار آمریکا میلیارد دلاری در سراسر جهان سازماندهی می‌کند[۱۸] در ماه آوریل حاکی از آن بود که واکسنی تحت پروتکل‌های استفادهٔ اضطراری در کمتر از ۱۲ ماه یا در اوایل سال ۲۰۲۱ ممکن است در دسترس باشد.[۱۹]

تا ماه مه، ۱۲۰ نامزد واکسن در حال توسعه بودند،[۱۹][۲۰] که پنج تا در فاز مطالعات ایمنی و کارایی در افراد انسانی I-II، و شش تا در فاز I آزمایش‌ها بودند.

وضعیت آزمایش و مجوز

ویرایش

واکسن‌های مجاز و تأیید شده

ویرایش

نهادهای ملی تاکنون به نه واکسن، جواز استفاده اضطراری داده‌اند. سه تا از این‌ها از سوی نهادهای نظارتی سختگیر تأیید شدند

واکسن‌های مجاز برای استفاده اضطراری یا تأیید شده برای استفاده کامل
واکسن، توسعه دهنده/حامی فناوری فاز در جریان (شرکت کنندگان) فاز تکمیل شده [الف] (شرکت کنندگان) جواز
واکسن کووید-۱۹ فایزر–بیوان‌تک (Comirnaty)[۲۱][۲۲][۲۳]
بیوان‌تک، فایزر، داروسازی فوسان 		واکسن ریبونوکلئیک اسید (modRNA به صورت کپسول در نانو ذره‌های لیپیدی) فاز III ‏(۴۳,۴۴۸)
تصادفی، کنترل شده با پلاسیبو.
نتایج مثبت در تحلیل موقت در ۱۸ نوامبر ۲۰۲۰ اعلام[۲۴]و گزارش دربارهٔ اثربخشی ۹۵٪ در ۱۰ دسامبر ۲۰۲۰ منتشر شد.[۲۵][۲۶]
مکان(ها): آلمان، ایالات متحده
مدت : ژوئیه ۲۰۲۰ – نوامبر ۲۰۲۰[۲۷][۲۸] 		فاز I–II ‏(۴۵)
پادتن‌های جی قوی بسیار چسبنده به آربی‌دی و آنتی‌بادی خنثی کننده ۷ روز پس از یک دوز یادآور به اوج خود رسیدند، پاسخ مقاوم لنفوسیت تی CD4+ و CD8+ , ماندگاری نامشخص.[۲۹]
مدت : مه ۲۰۲۰ –
اضطراری (۲۲)
کامل (۱۰)
واکسن کووید-۱۹ مدرنا[۷۱][۷۲]
مدرنا، مؤسسه ملی آلرژی و بیماری‌های عفونی، BARDA, CEPI 		واکسن ریبونوکلئیک اسید (modRNA قرار گرفته به صورت کپسول در ریزذره‌های لیپیدی) فاز III ‏(۳۰٬۰۰۰)
مداخله ای؛ مطالعه تصادفی، کنترل شده با پلاسیبو برای تضمین اثربخشی، ایمنی و ایمنی زایی انجام شده.
نتایج مثبت از یک آزمایش موقت در ۱۵ نوامبر ۲۰۲۰ اعلام شد[۷۳] و در ۳۰ دسامبر ۲۰۲۰ اثربخشی کل ۹۴٫۱٪ اعلام شد.[۷۴]
مکان(ها): ایالات متحده
مدت : ژوئیه 2020 – اکتبر ۲۰۲۲ 		فاز I–II ‏(۷۲۰)[۷۵][۷۶]
Dose-dependent neutralizing antibody response on two-dose schedule; undetermined durability.[۷۷][۷۸][۷۹]
مکان(ها): ایالات متحده
مدت : مارس 2020 – نوامبر ۲۰۲۱
اضطراری (۶)
کامل (۵)
ای‌زددی۱۲۲۲[پ][ت][۹۸][۹۹][۱۰۰]
دانشگاه آکسفورد، آسترازنکا، CEPI 		واکسن vector آدنوویروس (اصلاح شامپانزه معمولی وکتور آدنوویروس شامپانزه شده، ChAdOx1) فاز III ‏(۳۰۰۰۰)
مداخله‌ای؛ کارآزمایی تصادفی کنترل‌شده برای اثربخشی، ایمنی زایی و ایمنی.[۱۰۱]
نتایج یک تحلیل موقت از چهار آزمایش در جریان در ۲۳ نوامبر ۲۰۲۰ اعلام و در ۸ دسامبر ۲۰۲۰ منتشر شد. اثربخشی کل ۷۰٪ بود، و از ۶۲٪ تا ۹۰٪ در دزهای مختلف متغیر بود[۱۰۲]
مکان(ها): برزیل (۵٬۰۰۰),[۱۰۳] United Kingdom, India[۱۰۴]
مدت : May 2020 – Aug 2021 		فاز I–II ‏(۵۴۳)
Spike-specific antibodies at day 28; neutralizing antibodies پس از یک دوز یادآور at day 56.[۱۰۵]
اضطراری (۱۸)
کامل (۰)
  • هنوز ندارد
اسپوتنیک ۵ (Спутник V)
مرکز ملی تحقیقات اپیدمیولوژی و میکروبیولوژی گامالیا 		واکسن وکتوری آدنوویروس فاز III ‏(۴۰,۰۰۰)
آزمایش تصادفی، کور مضاعف، کنترل شده با پلاسیبو به منظور ارزیابی اثربخشی، ایمنی زایی و ایمنی.[۱۲۶]
تحلیل موقت از آزمایش‌ها منتشر شده در لنست, اثربخشی ۹۱٫۶٪ای بدون اثرات جانبی نامعمول را نشان می‌دهد.[۱۲۷]
مکان(ها): روسیه، بلاروس،[۱۲۸] هند،[۱۲۹][۱۳۰] ونزوئلا،[۱۳۱] امارات[۱۳۲]
مدت : اوت ۲۰۲۰ – مه ۲۰۲۱ 		فاز I–II ‏(۷۶)
پاسخ‌های آنتی‌بادی خنثی‌کننده و لنفوسیت تی.[۱۳۳]
مکان(ها): روسیه
مدت : ژوئن 2020[۱۳۳] – سپتامبر ۲۰۲۰
اضطراری (۱۵)
کامل (۰)
  • هنوز ندارد
بی‌بی‌آی‌بی‌پی-کروی[۱۴۸]
گروه دارویی ملی چین: Beijing Institute of Biological Products, Wuhan Institute of Biological Products 		واکسن کروناویروس سندرم شدید حاد تنفسی ۲ غیرفعال شده (vero cell) فاز III ‏(۴۸٬۰۰۰)
Randomized, double-blind, parallel placebo-controlled, to evaluate safety and protective efficacy.
Sinopharm's internal analysis indicated a 79% efficacy.[۱۴۹]
مکان(ها): United Arab Emirates, Bahrain, Jordan,[۱۵۰] Argentina,[۱۵۱] Morocco,[۱۵۲] Peru[۱۵۳]
مدت : ژوئیه 2020 – Jul ۲۰۲۱ 		فاز I–II ‏(۳۲۰)
Neutralizing antibodies at day 14 after 2 injections[۱۵۴]
مکان(ها): چین
مدت : Apr 2020 – ژوئن ۲۰۲۰
اضطراری (7)
Iran
کامل (۳)
کروناواک[۱۶۴][۱۶۵][۱۶۶]
Sinovac 		غیرفعال شده کروناویروس سندرم شدید حاد تنفسی ۲ vaccine فاز III ‏(۳۳,۶۲۰)
Double-blind, randomized, placebo-controlled to evaluate efficacy and safety.
Positive results from an interim analysis of a small sample were announced by ترکیه on 24 December 2020, with an efficacy of 91%.[۱۶۷] Additional results were announced by اندونزی on 11 January, with an overall efficacy of 65.3%.[۱۶۸] The vaccine was 50.4% effective at preventing symptomatic infections in a Brazilian trial.[۱۶۹]
مکان(ها): Brazil (15,000);[۱۷۰] Chile (3,000);[۱۷۱] Indonesia (1,620); Turkey (13,000)[۱۷۲]
مدت : ژوئیه 2020 – Oct 2021 in Brazil; اوت ۲۰۲۰ – Jan 2021 in Indonesia 		فاز II ‏(۶۰۰)
Immunogenicity eliciting 92% seroconversion at lower dose and 98% at higher dose after 14 days[۱۷۳]
مکان(ها): چین
مدت : May 2020 –
اضطراری (6)
کامل (۰)
  • None yet
Ad5-nCoV (Convidicea)
CanSino Biologics, Beijing Institute of Biotechnology of Academy of Military Medical Sciences 		آدنوویروس vector vaccine (واکسن adenovirus سروتیپ 5 vector) فاز III ‏(۴۰,۰۰۰)
Global multi-center, randomized, double-blind, placebo-controlled to evaluate efficacy, safety and immunogenicity.
مکان(ها): China, Argentina, Chile,[۱۷۹] Mexico,[۱۸۰] Pakistan,[۱۸۱] Russia,[۱۸۲] Saudi Arabia[۱۸۳][۱۸۴]
مدت : Mar. – Dec. 2020, China; Sep. 2020 – Dec. 2021, Pakistan; Sep. 2020 – Nov. 2020, Russia[۱۸۲] 		فاز II ‏(۵۰۸)
Neutralizing antibody and لنفوسیت تی responses[۱۸۵]
اضطراری (۱)
کامل (۰)
  • None yet
EpiVacCorona [ru][۱۸۸]
Vector 		Peptide vaccine[۱۸۸] فاز III ‏(۴۰,۰۰۰)
Randomized double-blind, placebo-controlled to evaluate efficacy, immunogenicity, and safety
مکان(ها): Russia[۱۸۹]
مدت : نوامبر ۲۰۲۰ – دسامبر ۲۰۲۱ 		فاز I–II ‏(۱۰۰)
Simple, blind, placebo-controlled, randomized study of safety, reactogenicity and immunogenicity[۱۸۸]
مکان(ها): Russia
مدت : ژوئیه 2020[۱۸۸] – Sep 2020[۱۹۰]
اضطراری (۱)
کامل (۰)
  • None yet
بی‌بی‌وی۱۵۲ (Covaxin)
بهارات بیوتک، Indian Council of Medical Research 		کروناویروس سندرم شدید حاد تنفسی ۲ vaccine فاز III ‏(۲۵٬۸۰۰)
Randomised, observer-blinded, placebo-controlled[۱۹۳]
مکان(ها): India[۱۹۴]
مدت : نوامبر 2020 – مارس ۲۰۲۱ 		فاز I ‏(۳۷۵)
Dose-dependent neutralizing antibody response on two-dose schedule. Pending Phase II reports.[۱۹۵]
اضطراری (۱)
کامل (۰)
  • None yet
SpikoGen COVID-19 Vaccine واکسن نوترکیب A Phase III, Randomized, Two-armed, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of an Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine Candidate (SpikoGen)[۱۹۶]

واکسن‌های کاندید

ویرایش
کاندیدهای واکسن کووید -۱۹ در آزمایش‌های فاز I–III[۹][۱۰][۱۱]
واکسن‌های کاندید،
توسعه دهنده‌ها، و حامیان 		فناوری فاز فعلی (شرکت کنندگان)
طراحی 		فاز تکمیل شده [ث] (شرکت کنندگان)
پاسخ ایمنی 		جواز در حال انتظار
Ad26.COV2.S [۱۹۷][۱۹۸]
جانسن فارماسیوتیکا (جانسون و جانسون), BIDMC 		آدنوویروس وکتور واکسن (adenovirus serotype 26) فاز III ‏(۴۰,۰۰۰)
Randomized, double-blinded, placebo-controlled
مکان(ها): ایالات متحده، Argentina, Brazil, Chile, Colombia, Mexico, Peru, the Philippines, South Africa and Ukraine
مدت : Jul 2020 – 2023 		فاز I–II ‏(۱٬۰۴۵)
Neutralizing-antibody titers against wild-type virus were detected in 90% or more of all participants on day 29 after the first vaccine dose and reached 100% by day 57 with a further increase in titers, regardless of vaccine dose or age group. Titers remained stable until at least day 71.[۱۹۹]
NVX-CoV2373 [۲۰۰]
Novavax, CEPI 		Subunit vaccine (کروناویروس سندرم شدید حاد تنفسی ۲ واکسن spike protein نانوذره with adjuvant) فاز III ‏(۴۵٬۰۰۰)
Randomised, observer-blinded, placebo-controlled trial[۲۰۱]
مکان(ها): UK (15,000); US, Mexico (30,000)[۲۰۲]
مدت : Sep 2020 – Jan 2021 (UK); Dec 2020 – Mar 2021 (US, Mexico) 		فاز I–II ‏(۱۳۱)
پادتن جی and neutralizing antibody response with adjuvant after دوز یادآور.[۲۰۳]
ZF2001 (RBD-Dimer)[۹]
Anhui Zhifei Longcom Biopharmaceutical Co. Ltd. 		Subunit vaccine (واکسن) فاز III ‏(۲۹٬۰۰۰)
Randomized, double-blind, placebo-controlled[۲۰۴]
مکان(ها): چین، Ecuador, Indonesia, Malaysia, Pakistan, Uzbekistan[۲۰۵][۲۰۶]
مدت : Dec 2020 – Apr 2022 		فاز II ‏(۹۰۰)
مداخله ای؛ randomized, double-blind, placebo-controlled[۲۰۷]
مکان(ها): چونگ‌کینگ
مدت : Jun 2020 – Sep 2021
Zorecimeran (CVnCoV)
CureVac, CEPI 		واکسن ریبونوکلئیک اسید (unmodified RNA)[۲۰۸] فاز III ‏(۳۶٬۵۰۰)[۲۰۹]
Phase 2b/3: Multicenter efficacy and safety trial in adults
مکان(ها): Argentina, Belgium, Colombia, Dominican Republic, France, آلمان، Mexico, Netherlands, Panama, Peru, Spain
مدت : Nov 2020 – ? 		فاز I–II ‏(۹۴۴)[۲۱۰][۲۱۱]
Phase 1 (284): Partially blind, controlled, dose-escalation to evaluate safety, reactogenicity and immunogenicity.
Phase 2a (660):Partially observer-blind, multicenter, controlled, dose-confirmation.
مکان(ها): Belgium (P1), آلمان (P1), Panama (2a), Peru (2a)
مدت : Jun 2020 – Oct 2021
ZyCoV-D[۲۱۲]
Cadila Healthcare 		DNA vaccine (پلاسمید expressing کروناویروس سندرم شدید حاد تنفسی ۲ S protein) فاز III ‏(۲۶٬۰۰۰)[۲۱۳]
مکان(ها): India[۲۱۴]
مدت : Jan 2021 – ? 		فاز I–II ‏(۱٬۰۰۰)
مداخله ای؛ randomized, double-blind, placebo-controlled[۲۱۵][۲۱۶]
مکان(ها): India
مدت : Jul 2020 – Jan 2021
CoVLP[۲۱۷]
Medicago, گلاکسواسمیت‌کلاین 		ذرات شبه‌ویروسs[ج] (واکسن، plant-based with AS03) فاز II–III ‏(۳۰٬۶۱۲)
Event-driven, randomized, observer blinded, placebo-controlled[۲۱۹]
مکان(ها): Canada
مدت : Nov 2020 – آوریل ۲۰۲۲ 		فاز I ‏(۱۸۰)
Neutralizing antibodies at day 42 after the first injection (day 21 after the second injection) were at levels 10x that of COVID-19 survivors.
IIBR-100 (Brilife)[۲۲۰]
The Israel Institute for Biological research 		Vesicular stomatitis vector vaccine (واکسن) فاز II ‏(۱٬۰۰۰)[۲۲۱]
مکان(ها): Israel
مدت : Dec 2020 – spring 2021 		فاز I ‏(۸۰)[۲۲۰]
Subjects (18-55 years old) randomly receiving a single administration of IIBR-100 at the low, mid, or high dose, or saline, or two administrations at a low dose, or saline, 28 days apart.
مکان(ها): Israel
مدت : Oct – Nov 2020
FINLAY-FR-2 (SOBERANA 02)
Instituto Finlay de Vacunas 		Conjugate vaccine[۲۲۲] فاز II ‏(۹۱۰)[۲۲۳]
Allocation: Randomized controlled trial. Masking: Double Blind. Control group: Placebo. Study design: Parallel.
مکان(ها): Cuba
مدت : Jan  – مارس ۲۰۲۱ 		فاز I ‏(۴۰)[۲۲۴]
Allocation: Non-randomized controlled trial. Masking: Open. Control group: Uncontrolled. Study design: Adaptive, sequential
مکان(ها): Cuba
مدت : نوامبر ۲۰۲۰  – ژانویه ۲۰۲۱
INO-4800[چ][۲۲۵][۲۲۶]
Inovio, CEPI, Korea National Institute of Health, International Vaccine Institute 		DNA vaccine (plasmid delivered by الکتروپوراسیون) فاز I–II ‏(۴۰)
مکان(ها): ایالات متحده، South Korea
مدت : Apr–Nov 2020 		پیشاکلینیکی
Pending Phase I report.
Unnamed[۲۲۷]
Chinese Academy of Medical Sciences 		غیرفعال شده کروناویروس سندرم شدید حاد تنفسی ۲ vaccine فاز I–II ‏(۹۴۲)
Randomized, double-blinded, single-center, placebo-controlled
مکان(ها): چنگدو
مدت : Jun 2020 – Sep 2021 		پیشاکلینیکی
AG0301-COVID‑19[۲۲۸]
AnGes Inc. ,[۲۲۹] AMED 		DNA vaccine (plasmid) فاز I–II ‏(۳۰)
Non-randomized, single-center, two doses
مکان(ها): اوساکا
مدت : Jun 2020 – Jul 2021 		پیشاکلینیکی
Lunar-COV19/ARCT-021[۲۳۰][۲۳۱]
Arcturus Therapeutics 		واکسن ریبونوکلئیک اسید فاز I–II ‏(۹۲)
Randomized, double-blinded
مکان(ها): Singapore
مدت : Aug 2020 – ? 		پیشاکلینیکی
VLA2001 [۲۳۲][۲۳۳]
Valneva 		غیرفعال شده کروناویروس سندرم شدید حاد تنفسی ۲ واکسن فاز I–II ‏(۱۵۰)
Randomized, multi-center, double-blinded
مکان(ها): United Kingdom
مدت : Dec 2020 – Feb 2021 		پیشاکلینیکی
COVID‑19/aAPC[۲۳۴]
Shenzhen Genoimmune Medical Institute[۲۳۵] 		Lentiviral vector vaccine (with minigene modifying aAPCs) فاز I ‏(۱۰۰)
مکان(ها): شنژن
مدت : مارس 2020 – ۲۰۲۳ 		پیشاکلینیکی
LV-SMENP-DC[۲۳۶]
Shenzhen Genoimmune Medical Institute[۲۳۵] 		Lentiviral vector vaccine (with minigene modifying سلول‌های دندریتیک) فاز I ‏(۱۰۰)
مکان(ها): شنژن
مدت : مارس 2020 – ۲۰۲۳ 		پیشاکلینیکی
LNP-nCoVsaRNA[۲۳۷]
شورای تحقیقات پزشکی (انگلستان) clinical trials unit در امپریال کالج لندن 		واکسن ریبونوکلئیک اسید فاز I ‏(۱۰۵)
Randomized trial, with dose escalation study (15) and expanded safety study (at least 200)
مکان(ها): United Kingdom
مدت : Jun 2020 – Jul 2021 		پیشاکلینیکی
GRAd-COV2[۲۳۸][۲۳۹]
ReiThera, Lazzaro Spallanzani National Institute for Infectious Diseases 		آدنوویروس vector vaccine (modified شامپانزه معمولی adenovirus vector, GRAd) فاز I ‏(۹۰)[۲۴۰]
Subjects (two groups: 18-55 and 65-85 years old) randomly receiving one of three escalating doses of GRAd-COV2 or a placebo, then monitored over a 24-week period. 92.5% of subjects who received GRAd-COV2 developed anti-bodies.
مکان(ها): رم
مدت : Aug – Dec 2020 		پیشاکلینیکی
GX-19[۲۴۱][۲۴۲]
Genexine consortium,[۲۴۳] International Vaccine Institute 		DNA vaccine فاز I ‏(۴۰)
مکان(ها): سئول
مدت : Jun 2020 – Jun 2022 		پیشاکلینیکی
SCB-2019[۲۴۴][۲۴۵]
Clover Biopharmaceuticals,[۲۴۶] گلاکسواسمیت‌کلاین، CEPI 		Subunit vaccine (Spike protein trimeric subunit with AS03) فاز I ‏(۱۵۰)
مکان(ها): پرت (استرالیا)
مدت : Jun 2020 – Mar 2021 		پیشاکلینیکی
COVAX-19[۲۴۷]
Vaxine Pty Ltd[۲۴۸] 		Subunit vaccine (واکسن پروتئین) فاز I ‏(۴۰)
مکان(ها): آدلاید
مدت : Jun 2020 – Jul 2021 		پیشاکلینیکی
Unnamed[۲۴۹]
PLA Academy of Military Science, Walvax Biotech[۲۵۰] 		واکسن ریبونوکلئیک اسید فاز I ‏(۱۶۸)
مکان(ها): چین
مدت : Jun 2020 – Dec 2021 		پیشاکلینیکی
HGC019[۲۵۱]
Gennova Biopharmaceuticals, HDT Biotech Corporation[۲۵۲] 		واکسن ریبونوکلئیک اسید فاز I ‏(۱۲۰)[۲۵۳]
مکان(ها): هند
مدت : Jan 2021 – 		پیشاکلینیکی
Bangavax [۲۵۴][۲۵۵] Globe Biotech Ltd of Bangladesh واکسن ریبونوکلئیک اسید فاز I ‏(۱۰۰)[۲۵۴][۲۵۶]
Randomized, Parallel Group Trial
مکان(ها): Bangladesh
مدت : Feb 2021 – Feb 2022[۲۵۷] 		پیشاکلینیکی
Unnamed[۲۵۸]
Biological E. Limited, کالج پزشکی بیلور[۲۵۹] 		غیرفعال شده کروناویروس سندرم شدید حاد تنفسی ۲ vaccine (using an antigen) فاز I–II ‏(۳۶۰)[۲۶۰]
Randomized, Parallel Group Trial
مکان(ها): India
مدت : Nov 2020 – Feb 2021 		پیشاکلینیکی
Nano Covax[۲۶۱]
Nanogen Pharmaceutical Biotechnology JSC 		واکسن spike protein[۲۶۲] فاز I ‏(۶۰)[۲۶۱]
مکان(ها): ویتنام
مدت : Dec 2020 – Jan 2021 		پیشاکلینیکی
Tested on mice, hamsters, and monkeys. Approved for human clinical trials by the Vietnam Ministry of Health.[۲۶۲]
PTX-COVID19-B[۲۶۳]
Providence Therapeutics 		واکسن ریبونوکلئیک اسید فاز I ‏(۶۰)[۲۶۳]
مکان(ها): کانادا
مدت : Jan 2021 – May 2021 		پیشاکلینیکی
SARS-CoV-2 Sclamp/V451[۲۶۴][۲۶۵]
دانشگاه کوئینزلند، Syneos Health, CEPI, Seqirus 		Subunit vaccine (molecular clamp stabilized spike protein with MF59) ? ‏(۱۲۰)
Randomised, double-blind, placebo-controlled, dose-ranging.
False positive HIV test found among participants.
مکان(ها): بریزبن
مدت : Jul–Oct 2020
V590[۲۶۶] and V591/MV-SARS-CoV-2[۲۶۷] مرک اند کو. (Themis BIOscience), انستیتو پاستور، University of Pittsburgh’s Center for Vaccine Research (CVR), CEPI Terminated[۲۶۸]
  1. ↑ جدیدترین فازی که نتایجش منتشر شده.
  2. ↑ ۲٫۰ ۲٫۱ جواز آمریکا همچنین کشورهای دارای حاکمیت ملی در پیمان اتحادیه آزاد را شامل می‌شود: پالائو، جزایر مارشال، و ایالات فدرال میکرونزی.[۵۳][۵۴]
  3. ↑ مؤسسه سرم هند آن را برای ChAdOx1  nCoV-19هند[۹۵] و دیگر کشورهای کم درآمد خواهد ساخت.[۹۶]
  4. ↑ Oxford name: ChAdOx1 nCoV-19. Manufacturing in Brazil to be carried out by Oswaldo Cruz Foundation.[۹۷]
  5. ↑ Latest Phase with published results.
  6. ↑ Virus-like particles grown in نیکوتیان[۲۱۸]
  7. ↑ South Korean Phase I–II in parallel with Phase I in the US

جستارهای وابسته

ویرایش

منابع

ویرایش
  1. ↑ Diamond, Michael S; Pierson, Theodore C (2020-05-13). "The challenges of vaccine development against a new virus during a pandemic". Cell Host and Microbe. 27 (5): 699–703. doi:10.1016/j.chom.2020.04.021. PMC 7219397. PMID 32407708.
  2. ↑ «COVID-19 vaccine tracker». vac-lshtm.shinyapps.io. دریافت‌شده در ۲۰۲۱-۰۲-۰۱.
  3. ↑ «COVID-19 vaccine tracker». vac-lshtm.shinyapps.io. دریافت‌شده در ۲۰۲۱-۰۶-۱۶.
  4. ↑ "Covid-19 vaccine: who are countries prioritising for first doses?". the Guardian (به انگلیسی). 2020-11-18. Retrieved 2021-02-01.
  5. ↑ «Coronavirus (COVID-19) Vaccinations - Statistics and Research». Our World in Data. دریافت‌شده در ۲۰۲۱-۰۶-۱۶.
  6. ↑ Mullard, Asher (2020-11-30). "How COVID vaccines are being divvied up around the world". Nature (به انگلیسی). doi:10.1038/d41586-020-03370-6.
  7. ↑ So, Anthony D; Woo, Joshua (2020-12-15). "Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis". The BMJ. 371. doi:10.1136/bmj.m4750. ISSN 0959-8138. PMC 7735431. PMID 33323376.
  8. ↑ ۸٫۰ ۸٫۱ Le, Tung Thanh; Cramer, Jakob P.; Chen, Robert; Mayhew, Stephen (2020-09-04). "Evolution of the COVID-19 vaccine development landscape". Nature Reviews Drug Discovery. 19 (10): 667–68. doi:10.1038/d41573-020-00151-8. ISSN 1474-1776. PMID 32887942. S2CID 221503034.
  9. ↑ ۹٫۰ ۹٫۱ ۹٫۲ "COVID-19 vaccine development pipeline (Refresh URL to update)". Vaccine Centre, London School of Hygiene and Tropical Medicine. 2020-11-16. Retrieved 2020-11-16.
  10. ↑ ۱۰٫۰ ۱۰٫۱ "COVID-19 vaccine tracker (Choose vaccines tab, apply filters to view select data)". Milken Institute. 2020-11-16. Retrieved 2020-11-09. Lay summary. {{cite web}}: Cite uses deprecated parameter |lay-url= (help)
  11. ↑ ۱۱٫۰ ۱۱٫۱ "Draft landscape of COVID 19 candidate vaccines". World Health Organization. 2020-11-12. Retrieved 2020-11-16.
  12. ↑ "Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study". Pfizer. Retrieved 9 November 2020.
  13. ↑ "Moderna's COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study | Moderna, Inc". investors.modernatx.com (به انگلیسی). Archived from the original on 30 November 2020. Retrieved 2020-11-27.
  14. ↑ "AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19". www.astrazeneca.com (به انگلیسی).
  15. ↑ "Oxford University breakthrough on global COVID-19 vaccine". www.research.ox.ac.uk (به انگلیسی).
  16. ↑ خطای یادکرد: خطای یادکرد:برچسب <ref>‎ غیرمجاز؛ متنی برای یادکردهای با نام gates2 وارد نشده است. (صفحهٔ راهنما را مطالعه کنید.).
  17. ↑ Grenfell, Rob; Drew, Trevor (17 February 2020). "Here's Why It's Taking So Long to Develop a Vaccine for the New Coronavirus". ScienceAlert. Archived from the original on 28 February 2020. Retrieved 26 February 2020.
  18. ↑ "CEPI welcomes UK Government's funding and highlights need for $2 billion to develop a vaccine against COVID-19". Coalition for Epidemic Preparedness Innovations, Oslo, Norway. 6 March 2020. Retrieved 23 March 2020.
  19. ↑ ۱۹٫۰ ۱۹٫۱ Thanh Le, Tung; Andreadakis, Zacharias; Kumar, Arun; Gómez Román, Raúl; Tollefsen, Stig; Saville, Melanie; Mayhew, Stephen (9 April 2020). "The COVID-19 vaccine development landscape". Nature Reviews Drug Discovery. 19 (5): 305–306. doi:10.1038/d41573-020-00073-5. ISSN 1474-1776. PMID 32273591.
  20. ↑ "Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine". World Health Organization. 2020-04-27. Retrieved 2020-05-02. It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. WHO is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale
  21. ↑ ۲۱٫۰ ۲۱٫۱ "Regulatory Decision Summary – Pfizer-BioNTech COVID-19 Vaccine". Health Canada, Government of Canada. 9 December 2020. Retrieved 9 December 2020.
  22. ↑ "Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 30 April 2020. NCT04368728. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  23. ↑ "A Multi-site Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults". EU Clinical Trials Register. European Union. 14 April 2020. EudraCT 2020-001038-36. Archived from the original on 22 April 2020. Retrieved 22 April 2020.
  24. ↑ "Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints". Pfizer. 18 November 2020.
  25. ↑ Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. (December 2020). "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine". New England Journal of Medicine. 383 (27): 2603–2615. doi:10.1056/NEJMoa2034577. PMC 7745181. PMID 33301246.
  26. ↑ FDA Review of Efficacy and Safety of Pfizer-BioNTech COVID-19 Vaccine Emergency Use Authorization Request (PDF). U.S. سازمان غذا و دارو (آمریکا) (FDA) (Report). 10 December 2020. Retrieved 11 December 2020.   This article incorporates text from this source, which is in the public domain.
  27. ↑ Erman, Michael (18 November 2020). "Pfizer ends COVID-19 trial with 95% efficacy, to seek emergency-use authorization". Reuters. Retrieved 18 November 2020.
  28. ↑ خطای یادکرد: خطای یادکرد:برچسب <ref>‎ غیرمجاز؛ متنی برای یادکردهای با نام NYT-20201120 وارد نشده است. (صفحهٔ راهنما را مطالعه کنید.).
  29. ↑ Mulligan, Mark J.; Lyke, Kirsten E.; Kitchin, Nicholas; Absalon, Judith; Gurtman, Alejandra; Lockhart, Stephen; et al. (October 2020). "Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults". Nature. 586 (7830): 589–593. doi:10.1038/s41586-020-2639-4. PMID 32785213. S2CID 221126922.
  30. ↑ "Albania to start COVID-19 immunisation with Pfizer vaccine in Jan – report". Seenews.
  31. ↑ "Coronavirus en la Argentina: La ANMAT aprobo el uso de emergencia de la vacuna Pfizer". La Nación (به اسپانیایی). Retrieved 23 December 2020.
  32. ↑ "Bahrain becomes second country to approve Pfizer COVID-19 vaccine". الجزیره (شبکه خبری). Retrieved 5 December 2020.
  33. ↑ ۳۳٫۰ ۳۳٫۱ "Drug and vaccine authorizations for COVID-19: List of applications received". Health Canada, Government of Canada. 9 December 2020. Retrieved 9 December 2020.
  34. ↑ "Chile approves Pfizer-BioNTech Covid-19 vaccine for emergency use". The Straits Times. 17 December 2020. Retrieved 17 December 2020.
  35. ↑ "Colombia regulator approves Pfizer-BioNTech vaccine for emergency use". رویترز. 6 January 2021. Archived from the original on 8 January 2021. Retrieved 6 January 2021.
  36. ↑ "Costa Rica authorizes Pfizer-BioNTech coronavirus vaccine". The Tico Times. 16 December 2020. Retrieved 16 December 2020.
  37. ↑ "Arcsa autoriza ingreso al país de vacuna Pfizer-BioNTech para el Covid-19 – Agencia Nacional de Regulación, Control y Vigilancia Sanitaria" (به اسپانیایی). Retrieved 17 December 2020.
  38. ↑ "Iraq grants emergency approval for Pfizer COVID-19 vaccine". MSN. Retrieved 27 December 2020.
  39. ↑ "Israeli Health Minister 'pleased' as FDA approves Pfizer COVID-19 vaccine". The Jerusalem Post. Retrieved 28 December 2020.
  40. ↑ "Jordan approves Pfizer-BioNTech Covid vaccine". France 24. 15 December 2020. Retrieved 15 December 2020.
  41. ↑ "Kuwait authorizes emergency use of Pfizer-BioNTech COVID-19 vaccine". Arab News. 13 December 2020. Retrieved 15 December 2020.
  42. ↑ "Mexico Approves Pfizer Vaccine for Emergency Use as Covid Surges". Bloomberg. 12 December 2020. Retrieved 12 December 2020.
  43. ↑ "Mexico authorizes emergency use of Pfizer-BioNTech coronavirus vaccine". The Economic Times. 12 December 2020. Retrieved 14 January 2021.
  44. ↑ "Oman issues licence to import Pfizer BioNTech Covid vaccine – TV". Reuters. 15 December 2020. Retrieved 16 December 2020.
  45. ↑ "Panama approves Pfizer's COVID-19 vaccine – health ministry". Yahoo! Finance. Retrieved 16 December 2020.
  46. ↑ "PH authorizes Pfizer's COVID-19 vaccine for emergency use". CNN Philippines. 14 January 2021. Archived from the original on 27 February 2021. Retrieved 14 January 2021.
  47. ↑ "Qatar, Oman to receive Pfizer-BioNTech COVID-19 vaccine this week". Reuters. Retrieved 24 December 2020.
  48. ↑ "Singapore approves use of Pfizer's COVID-19 vaccine". AP NEWS. 14 December 2020. Retrieved 15 December 2020.
  49. ↑ "Dubai approves the Pfizer-BioNTech vaccine which will be free of charge". Emirates Woman. 23 December 2020. Retrieved 28 December 2020.
  50. ↑ "UK medicines regulator gives approval for first UK COVID-19 vaccine". Medicines and Healthcare Products Regulatory Agency, Government of the UK. 2 December 2020. Retrieved 2 December 2020.
  51. ↑ "Information for Healthcare Professionals on Pfizer/BioNTech COVID-19 vaccine". Medicines & Healthcare products Regulatory Agency (MHRA). 8 December 2020. Retrieved 13 December 2020.
  52. ↑ "Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine". Medicines & Healthcare products Regulatory Agency (MHRA). 3 December 2020. Retrieved 13 December 2020.
  53. ↑ "Interior Applauds Inclusion of Insular Areas through Operation Warp Speed to Receive COVID-19 Vaccines" (Press release). وزارت کشور ایالات متحده آمریکا (DOI). 12 December 2020. Retrieved 13 January 2021.   This article incorporates text from this source, which is in the public domain.
  54. ↑ Dorman, Bill (6 January 2021). "Asia Minute: Palau Administers Vaccines to Keep Country Free of COVID". Hawaii Public Radio. Retrieved 13 January 2021.
  55. ↑ "FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine" (Press release). U.S. سازمان غذا و دارو (آمریکا) (FDA). 11 December 2020. Retrieved 11 December 2020.   This article incorporates text from this source, which is in the public domain.
  56. ↑ "Pfizer-BioNTech COVID-19 Vaccine EUA Fact Sheet for Healthcare Providers" (PDF). Pfizer. 11 December 2020.
  57. ↑ "WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access". سازمان جهانی بهداشت (WHO) (Press release). 31 December 2020. Retrieved 6 January 2021.
  58. ↑ "Comirnaty". Therapeutic Goods Administration. 25 January 2021. Archived from the original on 1 February 2021. Retrieved 25 January 2021.
  59. ↑ "Comirnaty EPAR". آژانس دارویی اروپا (EMA). Retrieved 23 December 2020.
  60. ↑ "Questions and Answers: COVID-19 vaccination in the EU". کمیسیون اروپا. 21 December 2020. Retrieved 21 December 2020.
  61. ↑ "Comirnaty". Union Register of medicinal products. Retrieved 8 January 2021.
  62. ↑ ۶۲٫۰ ۶۲٫۱ "Første vaccine mod COVID19 godkendt i EU". Lægemiddelstyrelsen (به دانمارکی). Retrieved 2020-12-26.
  63. ↑ "COVID-19: Bóluefninu Comirnaty frá BioNTech/Pfizer hefur verið veitt skilyrt íslenskt markaðsleyfi". Lyfjastofnun (به ایسلندی). Retrieved 2020-12-26.
  64. ↑ Lim, Ida (2021-01-08). "Khairy: Malaysia can use Pfizer's Covid-19 vaccine now as conditional registration granted". Malay Mail. Retrieved 2021-01-08.
  65. ↑ "Status på koronavaksiner under godkjenning per 21.12.20". Statens legemiddelverk (به نروژی بوک‌مُل). Archived from the original on 8 January 2021. Retrieved 2020-12-26.
  66. ↑ "Coronavirus: Saudi Arabia approves Pfizer COVID-19 vaccine for use". Al Arabiya English. 10 December 2020. Retrieved 10 December 2020.
  67. ↑ Zimmer, Carl; Corum, Jonathan; Wee, Sui-Lee (10 June 2020). "Coronavirus Vaccine Tracker". نیویورک تایمز. ISSN 0362-4331. Retrieved 12 December 2020.
  68. ↑ "Serbia leads region in expecting COVID-19 vaccines within days". BalkanInsight. 21 December 2020. Retrieved 26 December 2020.
  69. ↑ "First shipment of Pfizer-BioNTech vaccine arrives in Serbia". Serbian government website. 22 December 2020. Retrieved 26 December 2020.
  70. ↑ "Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland" (Press release). Swiss Agency for Therapeutic Products (Swissmedic). 19 December 2020. Retrieved 19 December 2020.
  71. ↑ "A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 14 July 2020. NCT04470427. Archived from the original on 11 October 2020. Retrieved 27 July 2020.
  72. ↑ Palca, Joe (27 July 2020). "COVID-19 vaccine candidate heads to widespread testing in U.S." NPR. Archived from the original on 11 October 2020. Retrieved 27 July 2020.
  73. ↑ "Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine". National Institutes of Health (NIH). 15 November 2020.
  74. ↑ Baden L, Essink B, Kotloff K, Frey S, Novak R, Diemert D, et al. (December 2020). "Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine". New England Journal of Medicine. doi:10.1056/NEJMoa2035389. PMID 33378609.
  75. ↑ "Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)". ClinicalTrials.gov.
  76. ↑ "Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older". ClinicalTrials.gov. Retrieved 19 December 2020.
  77. ↑ Widge, Alicia T.; Rouphael, Nadine G.; Jackson, Lisa A.; Anderson, Evan J.; Roberts, Paul C.; Makhene, Mamodikoe; et al. (3 December 2020). "Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination". New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmc2032195. ISSN 0028-4793. PMC 7727324. PMID 33270381.
  78. ↑ Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. (mRNA-1273 Study Group) (July 2020). "An mRNA Vaccine against SARS-CoV-2 – Preliminary Report". New England Journal of Medicine. 383 (20): 1920–1931. doi:10.1056/NEJMoa2022483. PMC 7377258. PMID 32663912. Lay summary. {{cite journal}}: Cite uses deprecated parameter |lay-url= (help)
  79. ↑ Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. (mRNA-1273 Study Group) (July 2020). "An mRNA Vaccine against SARS-CoV-2 – Preliminary Report Supplementary appendix". New England Journal of Medicine. doi:10.1056/NEJMoa2022483. PMID 32663912.
  80. ↑ "Regulatory Decision Summary – Moderna COVID-19 Vaccine – Health Canada". Health Canada, Government of Canada. 23 December 2020. Retrieved 23 December 2020.
  81. ↑ "Israeli Ministry of Health Authorizes COVID-19 Vaccine Moderna for Use in Israel". modernatx.com. 4 January 2021. Archived from the original on 17 February 2021. Retrieved 4 January 2021.
  82. ↑ ۸۲٫۰ ۸۲٫۱ "AstraZeneca and Moderna vaccines to be administered in Saudi Arabia". gulfnews.com (به انگلیسی). Retrieved 2021-01-19.
  83. ↑ "Swissmedic grants authorisation for the COVID-19 vaccine from Moderna" (Press release). Swiss Agency for Therapeutic Products (Swissmedic). 2020-01-12. Retrieved 2020-01-12.
  84. ↑ "Information for Healthcare Professionals on COVID-19 Vaccine Moderna". Medicines and Healthcare products Regulatory Agency (MHRA). 8 January 2021. Retrieved 8 January 2021.
  85. ↑ "Conditions of Authorisation for COVID-19 Vaccine Moderna". Medicines and Healthcare products Regulatory Agency (MHRA). 8 January 2021. Retrieved 9 January 2021.
  86. ↑ "FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine". U.S. سازمان غذا و دارو (آمریکا) (FDA) (Press release). Retrieved 18 December 2020.
  87. ↑ Oliver, Sara E.; Gargano, Julia W.; Marin, Mona; Wallace, Megan; Curran, Kathryn G.; Chamberland, Mary; et al. (December 2020). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine —ایالات متحده، December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1653–1656. doi:10.15585/mmwr.mm695152e1. PMID 33382675.
  88. ↑ "COVID-19 Vaccine Moderna EPAR". آژانس دارویی اروپا (EMA). Retrieved 20 January 2021.
  89. ↑ "European Commission authorises second safe and effective vaccine against COVID-19". European Commission (Press release). Retrieved 6 January 2021.
  90. ↑ "EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU" (Press release). European Medicines Agency. 6 January 2021. Retrieved 6 January 2021.
  91. ↑ "COVID-19 Vaccine Moderna". Union Register of medicinal products. Retrieved 14 January 2021.
  92. ↑ ۹۲٫۰ ۹۲٫۱ "Endnu en vaccine mod COVID-19 er godkendt af EU-Kommissionen". Lægemiddelstyrelsen (به دانمارکی). Retrieved 2021-01-07.
  93. ↑ "COVID-19: Bóluefninu COVID-19 Vaccine Moderna frá hefur verið veitt skilyrt íslenskt markaðsleyfi". Lyfjastofnun (به ایسلندی). Retrieved 2021-01-07.
  94. ↑ "Status på koronavaksiner under godkjenning per 6. januar 2021". Statens legemiddelverk (به نروژی بوک‌مُل). Archived from the original on 4 February 2021. Retrieved 2021-01-07.
  95. ↑ "AstraZeneca & Serum Institute of India sign licensing deal for 1 million doses of Oxford vaccine". The Economic Times. Retrieved 15 June 2020.
  96. ↑ "Covid-19 vaccine: Serum Institute signs up for 100 million doses of vaccines for India, low and middle-income countries". The Financial Express. 7 August 2020.
  97. ↑ Walsh, Nick; Shelley, Jo; Duwe, Eduardo; Bonnett, William (27 July 2020). "The world's hopes for a coronavirus vaccine may run in these health care workers' veins". سائو پائولو: سی‌ان‌ان. Archived from the original on 3 August 2020. Retrieved 3 August 2020.
  98. ↑ "Investigating a Vaccine Against COVID-19". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 26 May 2020. NCT04400838. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  99. ↑ "A Phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19". EU Clinical Trials Register. European Union. 21 April 2020. EudraCT 2020-001228-32. Archived from the original on 5 October 2020. Retrieved 3 August 2020.
  100. ↑ O'Reilly, Peter (26 May 2020). "A Phase III study to investigate a vaccine against COVID-19". ISRCTN. doi:10.1186/ISRCTN89951424. ISRCTN89951424.
  101. ↑ "A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 12 May 2020. NCT04383574. Archived from the original on 23 August 2020. Retrieved 26 August 2020.
  102. ↑ "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK – The Lancet". Retrieved 9 December 2020.
  103. ↑ "Trial of Oxford COVID-19 vaccine starts in Brazil". Jenner Institute. Archived from the original on 9 September 2020. Retrieved 26 August 2020.
  104. ↑ "Oxford COVID-19 vaccine final trials will be held in these 17 hospitals in India". mint. 19 August 2020.
  105. ↑ Folegatti, Pedro M; Ewer, Katie J; Aley, Parvinder K; Angus, Brian; Becker, Stephan; Belij-Rammerstorfer, Sandra; et al. (July 2020). "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial". Lancet. 396 (10249): 467–78. doi:10.1016/S0140-6736(20)31604-4. PMC 7445431. PMID 32702298. Lay summary. {{cite journal}}: Cite uses deprecated parameter |lay-url= (help)
  106. ↑ "Argentine regulator approves AstraZeneca/Oxford COVID-19 vaccine". Reuters. 30 December 2020. Retrieved 30 December 2020.
  107. ↑ https://saudigazette.com.sa/article/602862
  108. ↑ "Oxford University-Astrazeneca vaccine: Bangladesh okays it for emergency use". thedailystar.net. Retrieved 2021-01-06.
  109. ↑ "Bangladesh approves Oxford-AstraZeneca COVID-19 vaccine". aa.com.tr. Retrieved 2021-01-06.
  110. ↑ ۱۱۰٫۰ ۱۱۰٫۱ McGeever, Jamie; Fonseca, Pedro (17 January 2021). "Brazil clears emergency use of Sinovac, AstraZeneca vaccines, shots begin". Reuters. Retrieved 17 January 2021.
  111. ↑ Staff, Agencia EFE (31 December 2020). "La República Dominicana aprueba la vacuna de AstraZeneca contra la covid-19". Agencia EFE (به اسپانیایی). Archived from the original on 24 January 2021. Retrieved 27 January 2021.
  112. ↑ https://www.reuters.com/article/health-coronavirus-ecuador-astrazeneca/ecuador-approves-use-of-astrazeneca-vaccine-for-covid-19-idUSL1N2JZ0HC
  113. ↑ "El Salvador greenlights AstraZeneca, Oxford University COVID-19 vaccine". Reuters. 30 December 2020.
  114. ↑ ۱۱۴٫۰ ۱۱۴٫۱ "Hungarian drug regulator approves Sputnik V vaccine: website". Reuters. 21 January 2021.
  115. ↑ ۱۱۵٫۰ ۱۱۵٫۱ Schmall, Emily; Yasir, Sameer (3 January 2021). "India Approves Oxford-AstraZeneca Covid-19 Vaccine and 1 Other". The New York Times. Retrieved 3 January 2021.
  116. ↑ ۱۱۶٫۰ ۱۱۶٫۱ https://www.bignewsnetwork.com/news/267583081/iraq-approves-sinopharm-astrazeneca-vaccines
  117. ↑ "Mexico approves AstraZeneca COVID-19 vaccine, minister says". Reuters. 5 January 2021. Retrieved 14 January 2021.
  118. ↑ "Myanmar launches nationwide COVID-19 vaccination program". Xinhua News. January 27th 2021. {{cite news}}: Check date values in: |date= (help)
  119. ↑ Staff, Reuters (15 January 2021). "Nepal approves AstraZeneca COVID vaccine for emergency use - government statement". Reuters (به انگلیسی).
  120. ↑ Staff, Reuters (16 January 2021). "Pakistan approves AstraZeneca COVID-19 vaccine for emergency use" (به انگلیسی).
  121. ↑ "Sri Lanka approves vaccine amid warnings of virus spread". AP NEWS. 2021-01-22. Retrieved 2021-01-22.
  122. ↑ https://www.pattayamail.com/thailandnews/thai-food-and-drug-registers-covid-19-vaccine-developed-by-astrazeneca-341186
  123. ↑ "Information for Healthcare Professionals on COVID-19 Vaccine AstraZeneca". Medicines and Healthcare products Regulatory Agency (MHRA). 30 December 2020. Retrieved 4 January 2021.
  124. ↑ "Oxford University/AstraZeneca vaccine authorised by UK medicines regulator" (Press release). Department of Health and Social Care. 30 December 2020. Retrieved 30 December 2020.
  125. ↑ "Conditions of Authorisation for COVID-19 Vaccine AstraZeneca". Medicines and Healthcare products Regulatory Agency (MHRA). 30 December 2020. Retrieved 4 January 2021.
  126. ↑ "Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19". ClinicalTrials.gov. Archived from the original on 12 September 2020. Retrieved 11 September 2020.
  127. ↑ Logunov, Denis Y.; Dolzhikova, Inna V.; Shcheblyakov, Dmitry V.; Tukhvatulin, Amir I.; Zubkova, Olga V.; Dzharullaeva, Alina S.; Kovyrshina, Anna V.; Lubenets, Nadezhda L.; Grousova, Daria M.; Erokhova, Alina S.; Botikov, Andrei G. (2021-02-02). "Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia". The Lancet (به انگلیسی). 0 (0). doi:10.1016/S0140-6736(21)00234-8. ISSN 0140-6736.
  128. ↑ "Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus". ClinicalTrials.gov (به انگلیسی). Health Ministry of the Russian Federation. 25 September 2020. Retrieved 18 January 2021.
  129. ↑ Kumar, Shivani (1 December 2020). "Sputnik-V from Russia arrives in India for clinal trials". Hindustan Times.
  130. ↑ "Clinical trial: 17 volunteers given Russia's Sputnik V Covid-19 vaccine in Pune". The Indian Express. 6 December 2020.
  131. ↑ "Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Vaccine Against COVID-19 in Venezuela". ClinicalTrials.gov (به انگلیسی). Health Ministry of the Russian Federation. 24 November 2020. Retrieved 18 January 2021.
  132. ↑ "UAE begins trials of Russia's Sputnik V Covid-19 vaccine". ClinicalTrials. 8 January 2021.
  133. ↑ ۱۳۳٫۰ ۱۳۳٫۱ Logunov, Denis Y; Dolzhikova, Inna V; others (2020). "Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia". The Lancet. 396 (10255): 887–97. doi:10.1016/s0140-6736(20)31866-3. ISSN 0140-6736. PMC 7471804. PMID 32896291. S2CID 221472251.
  134. ↑ "Covid19: National Pharmaceuticals Agency registers Sputnik V vaccine". Algeria Press service. 10 January 2021.
  135. ↑ "Argentina has registered the Sputnik V vaccine based on Russian clinical trial data". sputnikvaccine.com. Retrieved 1 January 2021.
  136. ↑ "Belarus registers Sputnik V vaccine, in first outside Russia - RDIF". Reuters. 21 December 2020. Retrieved 22 December 2020.
  137. ↑ "Ministerio de Salud de Bolivia - Bolivia y Rusia firman contrato para adquirir 5,2 millones de dosis de la vacuna Sputnik-V contra la COVID-19". www.minsalud.gob.bo. Retrieved 1 January 2021.
  138. ↑ "Guinea Begins Administering Russia's Sputnik V Covid-19 Vaccine". africanews. 31 December 2020.
  139. ↑ "Iran approves Russian coronavirus vaccine Sputnik V". Reuters. 26 January 2021.
  140. ↑ "Govt okays Russian vaccine for 'emergency use'". Dawn. 24 January 2021.
  141. ↑ "Palestine has become the first country in the Middle East to register Sputnik V vaccine". RFID. 11 January 2021. Archived from the original on 5 February 2021. Retrieved 27 January 2021.
  142. ↑ "Paraguay approves Russia's Sputnik V vaccine: RDIF". Reuters. 15 January 2021. Retrieved 15 January 2021.
  143. ↑ Burki TK (November 2020). "The Russian vaccine for COVID-19". The Lancet. Respiratory Medicine. 8 (11): e85–e86. doi:10.1016/S2213-2600(20)30402-1. PMID 32896274.
  144. ↑ "Agencija odobrila uvoz ruske vakcine Sputnjik V u Srbiju". N1 (به صربی). 31 December 2020.
  145. ↑ "Turkmenistan is the first in Central Asia to have registered "Sputnik V» vaccine". Orient (به انگلیسی). 18 January 2021. Archived from the original on 27 January 2021. Retrieved 27 January 2021.
  146. ↑ "UAE approves Russia's Sputnik vaccine for emergency use". Khaleej Times. 21 January 2021. Retrieved 21 January 2021.
  147. ↑ "Venezuela firma contrato para la adquisición de la vacuna rusa Sputnik V" (به اسپانیایی). Reuters. 29 December 2020.
  148. ↑ Chen, Wei; Al Kaabi, Nawal (18 July 2020). "A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells)". Chinese Clinical Trial Registry. Archived from the original on 11 October 2020. Retrieved 15 August 2020.
  149. ↑ Wee, Sui-Lee; Qin, Amy (2020-12-30). "A Chinese Covid-19 Vaccine Has Proved Effective, Its Maker Says". The New York Times. ISSN 0362-4331. Retrieved 2020-12-30.
  150. ↑ Yang, Yunkai. "A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above". ClinicalTrials.gov. Archived from the original on 14 September 2020. Retrieved 15 September 2020.
  151. ↑ "Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)". ClinicalTrials.gov. Retrieved 28 September 2020.
  152. ↑ "A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells)". chictr.org.cn. Chinese Clinical Trial Register (ChiCTR). Archived from the original on 31 December 2020. Retrieved 15 December 2020.
  153. ↑ "Bahrain allows Sinopharm COVID-19 vaccine candidate use in frontline workers". MSN. Reuters. Retrieved 3 November 2020.
  154. ↑ Xia S, Duan K, Zhang Y, Zhao D, et al. (13 August 2020). "Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials". JAMA. 324 (10): 951–960. doi:10.1001/jama.2020.15543. PMC 7426884. PMID 32789505.
  155. ↑ http://xinhuanet.com/english/2021-01/03/c_139637781.htm
  156. ↑ "First batch of Chinese Sinopharm vaccine arrives in Jordan". Roya News. Archived from the original on 4 February 2021. Retrieved 9 January 2021.
  157. ↑ https://en.yabiladi.com/articles/details/104807/covid-19-morocco-authorizes-sinopharm-vaccine.html
  158. ↑ https://www.reuters.com/article/health-coronavirus-pakistan-sinopharm/pakistan-approves-chinese-sinopharm-covid-19-vaccine-for-emergency-use-idUSKBN29O049
  159. ↑ https://www.rferl.org/a/serbia-covid-vaccine-china-sinopharm/31053091.html
  160. ↑ https://www.arabianbusiness.com/healthcare/455832-bahrain-approves-chinas-sinopharm-coronavirus-vaccine
  161. ↑ https://www.washingtonpost.com/world/asia_pacific/coronavirus-vaccine-china-sinopharm/2020/12/30/1cc4be9e-4a62-11eb-97b6-4eb9f72ff46b_story.html
  162. ↑ Wee, Sui-Lee (9 December 2020). "Chinese Covid-19 Vaccine Gets Key Push, but Doubts Swirl". نیویورک تایمز. Retrieved 12 December 2020.
  163. ↑ "Coronavirus: UAE authorises emergency use of vaccine for frontline workers". The National. Retrieved 24 November 2020.
  164. ↑ "Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection (COVID-19) (Renqiu)". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 12 May 2020. NCT04383574. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  165. ↑ "Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV)". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 2 July 2020. NCT04456595. Archived from the original on 11 October 2020. Retrieved 3 August 2020.
  166. ↑ PT. Bio Farma (10 August 2020). "A Phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-COV-2 inactivated vaccine in healthy adults aged 18–59 years in Indonesia". Registri Penyakit Indonesia. Retrieved 15 August 2020.
  167. ↑ "Turkish official says CoronaVac vaccine 91.25% effective". ABC News. Associated Press. Retrieved 28 December 2020.
  168. ↑ ۱۶۸٫۰ ۱۶۸٫۱ Soeriaatmadja, Wahyudi (2021-01-11). "Indonesia grants emergency use approval to Sinovac's vaccine, local trials show 65% efficacy". استریتس تایمز. Retrieved 2021-01-11.
  169. ↑ "CoronaVac's Overall Efficacy in Brazil Measured at 50.4%". Bloomberg. 12 January 2021. Retrieved 12 January 2021.
  170. ↑ "Tests show coronavirus vaccine by China's Sinovac is safe, says Brazil's Butantan Institute". Archived from the original on 29 October 2020. Retrieved 29 October 2020.
  171. ↑ "Chile initiates clinical study for COVID-19 vaccine". Archived from the original on 11 October 2020. Retrieved 29 October 2020.
  172. ↑ "Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated". ClinicalTrials.gov. 8 October 2020. Archived from the original on 20 October 2020. Retrieved 22 October 2020.
  173. ↑ Zhang, Yanjun; Zeng, Gang; Pan, Hongxing; Li, Changgui; Hu, Yaling; Chu, Kai; et al. (November 2020). "Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial". The Lancet Infectious Diseases. 0. doi:10.1016/S1473-3099(20)30843-4. PMID 33217362. S2CID 227099817.
  174. ↑ "Bolívia autoriza uso de vacinas Sputnik V e CoronaVac contra covid-19". noticias.uol.com.br (به پرتغالی). Retrieved 6 January 2021.
  175. ↑ Wu, Huizhong (6 December 2020). "چین prepares large-scale rollout of domestically-produced coronavirus vaccines". The Globe and Mail. Retrieved 7 December 2020.
  176. ↑ https://www.france24.com/es/minuto-a-minuto/20210120-chile-aprueba-el-uso-de-emergencia-de-la-vacuna-china-de-sinovac-contra-covid-19
  177. ↑ "BPOM Grants Emergency Use Authorization for Sinovac Vaccine". Tempo. 2021-01-11. Retrieved 2021-01-11.
  178. ↑ "Turkey to begin COVID-19 vaccine jabs by this weekend". Anadolu. 2021-01-11. Retrieved 2021-01-11.
  179. ↑ Lazcano, Patricio (15 November 2020). "Así funcionan las cuatro vacunas que se probarán en Chile". La Tercera. Retrieved 15 December 2020.
  180. ↑ Martinez, Ana Isabel (3 November 2020). "CanSino Biologics delivers COVID-19 vaccine to Mexico for late-stage trial". Reuters. Retrieved 4 November 2020.
  181. ↑ Ng, Eric (28 October 2020). "چین's CanSino trials Covid-19 vaccine in 'high disease burden' nations". South China Morning Post. Retrieved 4 November 2020.
  182. ↑ ۱۸۲٫۰ ۱۸۲٫۱ "Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 13 November 2020. NCT04540419. Retrieved 17 November 2020.
  183. ↑ Nafisa, Eltahir (9 August 2020). "CanSino to start Phase III trial of COVID-19 vaccine in Saudi". Reuters. Retrieved 4 November 2020.
  184. ↑ Gou, Jinbo. "Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above". ClinicalTrials.gov. Archived from the original on 18 September 2020. Retrieved 17 September 2020.
  185. ↑ Zhu, Feng-Cai; Guan, Xu-Hua; Li, Yu-Hua; Huang, Jian-Ying; Jiang, Tao; Hou, Li-Hua; et al. (July 2020). "Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial". Lancet. 396 (10249): 479–88. doi:10.1016/s0140-6736(20)31605-6. ISSN 0140-6736. PMID 32702299. Lay summary. {{cite journal}}: Cite uses deprecated parameter |lay-url= (help)
  186. ↑ "CanSino's COVID-19 vaccine approved for military use in China". Nikkei Asia. Archived from the original on 7 March 2021. Retrieved 24 December 2020.
  187. ↑ "More Than 2.7 Million People Have Gotten Vaccines: Covid-19 Tracker". Bloomberg L.P. Retrieved 24 December 2020.
  188. ↑ ۱۸۸٫۰ ۱۸۸٫۱ ۱۸۸٫۲ ۱۸۸٫۳ "Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19 (EpiVacCorona)". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 22 September 2020. NCT04368988. Retrieved 16 November 2020.
  189. ↑ "Russian EpiVacCorona Vaccine Has No Adverse Effects". OREANDA-NEWS. 13 January 2021.
  190. ↑ "Over 1,400 volunteers get Russia's first EpiVacCorona vaccine jab". TASS. 15 December 2020.
  191. ↑ "О регистрации вакцины ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора «ЭпиВакКорона»". Rospotrebnadzor (به روسی). 14 October 2020. Archived from the original on 1 November 2020. Retrieved 27 January 2021.
  192. ↑ "Russia's EpiVacCorona vaccine post-registration trials started". The Pharma Letter. 18 November 2020.
  193. ↑ "An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers". ClinicalTrials.gov. NCT04641481. Retrieved 26 November 2020.
  194. ↑ "Bharat Biotech Recruits 23,000 Volunteers For Covaxin's Phase 3 Clinical Trial". NDTV.com. 28 December 2020. Retrieved 3 January 2021.
  195. ↑ "Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers". ClinicalTrials.gov. NCT04471519.
  196. ↑ Cinnagen (2021-10-04). "A Phase III, Randomized, Two-armed, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of an Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine Candidate (SpikoGen)". Vaxine Pty Ltd. {{cite journal}}: Cite journal requires |journal= (help)
  197. ↑ "A Study of Ad26.COV2.S in Adults". ClinicalTrials.gov. 4 August 2020. Archived from the original on 16 September 2020. Retrieved 23 August 2020.
  198. ↑ "A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants". ClinicalTrials.gov. US National Library of Medicine. Archived from the original on 26 September 2020.
  199. ↑ Sadoff J, Shukarev G, Heerwegh D, Truyers C, Leroux-Roels I, LeGars M, et al. (January 2021). "Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine". New England Journal of Medicine. doi:10.1056/NEJMoa2034201. PMID 33440088.
  200. ↑ "Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 30 April 2020. NCT04368988. Archived from the original on 14 July 2020. Retrieved 14 July 2020.
  201. ↑ "A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom". ClinicalTrials.gov. Retrieved 22 November 2020.
  202. ↑ "A Study Looking at the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults at Risk for SARS-CoV-2". ClinicalTrials.gov. Retrieved 2020-12-30.
  203. ↑ Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. (September 2020). "Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine". The New England Journal of Medicine. 383 (24): 2320–2332. doi:10.1056/NEJMoa2026920. PMC 7494251. PMID 32877576.
  204. ↑ "A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19". ClinicalTrials.gov.
  205. ↑ Pinghui, Zhuang (20 November 2020). "Fifth Chinese Covid-19 vaccine candidate ready to enter phase 3 trials". South China Morning Post. Retrieved 26 December 2020.
  206. ↑ Ying, Teoh Pei (7 December 2020). "MYEG to conduct phase 3 clinical trial for China's Covid-19 vaccine in Msia | New Straits Times". New Straits Times. Retrieved 28 December 2020.
  207. ↑ "A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 10 July 2020. NCT04466085. Archived from the original on 28 July 2020. Retrieved 26 August 2020.
  208. ↑ "COVID-19". CureVac. Retrieved 2020-12-21.
  209. ↑ "COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older". EU Clinical Trials Register. 19 November 2020. 2020-003998-22. Retrieved 19 December 2020.
  210. ↑ "A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults". ClinicalTrials.gov. 26 June 2020. NCT04449276. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  211. ↑ "A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults". ClinicalTrials.gov. 17 August 2020. NCT04515147. Archived from the original on 23 August 2020. Retrieved 28 August 2020.
  212. ↑ "A prospective, randomized, adaptive, phase I/II clinical study to evaluate the safety and immunogenicity of Novel Corona Virus −2019-nCov vaccine candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects". ctri.nic.in. Clinical Trials Registry India. 15 December 2020. CTRI/2020/07/026352. Archived from the original on 22 November 2020.
  213. ↑ "Coronavirus | Zydus Cadila gets DCGI nod to initiate Phase-3 clinical trials for COVID-19 vaccine". The Hindu. 3 January 2021.
  214. ↑ "DBT-BIRAC supported indigenously developed DNA Vaccine Candidate by Zydus Cadila, approved for Phase III clinical trials". pib.gov.in. Press Information Bureau. 3 January 2021.
  215. ↑ Rawat, Kajal; Kumari, Puja; Saha, Lekha (24 November 2020). "COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies". European Journal of Pharmacology. 892: 173751. doi:10.1016/j.ejphar.2020.173751. ISSN 1879-0712. PMC 7685956. PMID 33245898.
  216. ↑ Thacker, Teena. "Zydus Cadila to test ZyCoV-D on 30,000 patients in Phase-3 trials". The Economic Times. Retrieved 16 December 2020.
  217. ↑ "GSK, Medicago launch phase 2/3 clinical trials of plant-derived COVID-19 vaccine". PMLive. 13 November 2020. Retrieved 16 November 2020.
  218. ↑ Chander, Vishwadha (14 July 2020). "Canada's Medicago begins human trials of plant-based COVID-19 vaccine". National Post. Reuters. Archived from the original on 1 November 2020. Retrieved 14 July 2020.
  219. ↑ Medicago (18 November 2020). "Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years of Age or Older". Clinical Trials. Retrieved 26 November 2020.
  220. ↑ ۲۲۰٫۰ ۲۲۰٫۱ "A Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 1 November 2020. NCT04608305.
  221. ↑ "As Israel goes vaccine-wild, will the homegrown version lose its shot?". Times of Israel. 29 December 2020. Retrieved 1 January 2021.{{cite web}}: نگهداری CS1: url-status (link)
  222. ↑ "Cuban scientists start second phase of Soberana 02 vaccine". Prensa Latina. 22 December 2020. Retrieved 22 January 2021.
  223. ↑ "SOBERANA 02A". Registro Público Cubano de Ensayos Clínicos. 17 December 2020. Archived from the original on 27 December 2020. Retrieved 22 January 2021.
  224. ↑ "SOBERANA 02". Registro Público Cubano de Ensayos Clínicos. 27 October 2020. Archived from the original on 26 January 2021. Retrieved 22 January 2021.
  225. ↑ "Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 7 April 2020. NCT04336410. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  226. ↑ "IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO's COVID-19 DNA vaccine in South Korea". International Vaccine Institute. 16 April 2020. Retrieved 23 April 2020.
  227. ↑ "Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 2 June 2020. NCT04412538. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  228. ↑ "Study of COVID-19 DNA Vaccine (AG0301-COVID19)". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 9 July 2020. NCT04463472. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  229. ↑ "About AnGes – Introduction". AnGes, Inc. Archived from the original on 11 October 2020. Retrieved 1 August 2020.
  230. ↑ "CTI and Arcturus Therapeutics Announce Initiation of Dosing of COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study". UK BioIndustry Association. 13 August 2020. Archived from the original on 11 October 2020. Retrieved 23 August 2020.
  231. ↑ "Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects". clinicaltrials.gov. Archived from the original on 11 October 2020. Retrieved 23 August 2020.
  232. ↑ "VLA2001 COVID-19 Vaccine". Precision Vaccinations. 31 December 2020. Retrieved 11 January 2021.
  233. ↑ "Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactiviated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults". clinicaltrials.gov. U.S. National Library of Medicine. 30 December 2020. Retrieved 11 January 2021.
  234. ↑ "Safety and Immunity of Covid-19 aAPC Vaccine". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 9 March 2020. NCT04299724. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  235. ↑ ۲۳۵٫۰ ۲۳۵٫۱ "About Us". Shenzhen Genoimmune Medical Institute. Archived from the original on 11 October 2020. Retrieved 1 August 2020.
  236. ↑ "Immunity and Safety of Covid-19 Synthetic Minigene Vaccine". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 19 February 2020. NCT04276896. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  237. ↑ Ward, Denise; McCormack, Sheena (22 May 2020). "Clinical trial to assess the safety of a coronavirus vaccine in healthy men and women". ISRCTN. doi:10.1186/ISRCTN17072692. ISRCTN17072692.
  238. ↑ "GRAd-COV2 Vaccine Against COVID-19". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 7 January 2021. NCT04528641.
  239. ↑ "ReiThera Announces its GRAd-COV2 COVID-19 Vaccine Candidate is Well Tolerated and Induces Clear Immune Responses in Healthy Subjects Aged 18-55 Years". ReiThera Srl. Yahoo! Finance. 24 November 2020. Retrieved 12 January 2021.
  240. ↑ "New ReiThera vaccine safe, response peak at 4 wks". آجنزیا ناتزیوناله استامپا آسوچاتا. 5 January 2021.
  241. ↑ "Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 24 June 2020. NCT04445389. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  242. ↑ "S. Korea's Genexine begins human trial of coronavirus vaccine". Reuters. 19 June 2020. Archived from the original on 11 October 2020. Retrieved 25 June 2020.
  243. ↑ "Genexine consortium's Covid-19 vaccine acquires approval for clinical trails in Korea". 11 June 2020. Retrieved 1 August 2020.
  244. ↑ "SCB-2019 as COVID-19 Vaccine". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 28 May 2020. NCT04405908. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  245. ↑ "Clover Biopharmaceuticals starts Phase I Covid-19 vaccine trial". Clinical Trials Arena. 20 June 2020. Archived from the original on 11 October 2020. Retrieved 25 June 2020.
  246. ↑ "About Us". Clover Biopharmaceuticals. Archived from the original on 11 October 2020. Retrieved 1 August 2020.
  247. ↑ "Monovalent Recombinant COVID19 Vaccine (COVAX19)". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 1 July 2020. NCT04453852. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  248. ↑ "Vaxine". Archived from the original on 11 October 2020. Retrieved 1 August 2020.
  249. ↑ "A Phase I clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18–59 years and 60 years and above". Chinese Clinical Trial Register. 24 June 2020. ChiCTR2000034112. Archived from the original on 11 October 2020. Retrieved 6 July 2020.
  250. ↑ "Company introduction". Walvax Biotechnology. Archived from the original on 11 October 2020. Retrieved 1 August 2020.
  251. ↑ "Indigenous mRNA vaccine candidate supported by DBT gets Drug Controller nod to initiate Human clinical trials". pib.gov.in. Press Information Bureau. Retrieved 13 January 2021.
  252. ↑ "mRNA Vaccines – HGC019". Gennova Biopharmaceuticals Limited. Retrieved 13 January 2021.
  253. ↑ Raghavan, Prabha (15 December 2020). "Pune-based Gennova to begin human trials of its Covid vaccine 'soon'". The Indian Express.
  254. ↑ ۲۵۴٫۰ ۲۵۴٫۱ "Bangavax Vaccine: Permission sought for clinical trial". thedailystar.net. The Daily Star. 18 January 2021.
  255. ↑ "Bangladesh joins global COVID-19 vaccine race with Bongavax set for clinical trial". arabnews.com. عرب نیوز. 8 January 2021.
  256. ↑ "Globe Biotech applies for approval to run clinical trial of COVID vaccine". bdnews24.com. Bdnews24.com. 17 January 2021.
  257. ↑ "Globe Biotech seeks approval for vaccine trials". newagebd.net. New Age. 17 January 2021.
  258. ↑ "A prospective open label randomised phase-I seamlessly followed by phase-II study to assess the safety, reactogenicity and immunogenicity of Biological E's novel Covid-19 vaccine containing Receptor Binding Domain of SARS-CoV-2 for protection against Covid-19 disease when administered intramuscularly in a two dose schedule (0, 28D) to healthy volunteers". ctri.nic.in. Clinical Trials Registry India. 13 January 2021. CTRI/2020/11/029032. Archived from the original on 12 November 2020.
  259. ↑ Chui, Molly (16 November 2020). "Biological E. Limited and Baylor COVID-19 vaccine begins clinical trial in India". کالج پزشکی بیلور.
  260. ↑ Leo, Leroy (16 November 2020). "Biological E initiates human trials of vaccine". Mint.
  261. ↑ ۲۶۱٫۰ ۲۶۱٫۱ "VN starts injection of homegrown COVID-19 vaccine in first-stage human trial". Viet Nam News. 17 December 2020.
  262. ↑ ۲۶۲٫۰ ۲۶۲٫۱ "How much does first Made-in Vietnam COVID-19 vaccine cost?". Voice of Vietnam. 11 December 2020.
  263. ↑ ۲۶۳٫۰ ۲۶۳٫۱ "Made-in-Canada coronavirus vaccine starts human clinical trials". cbc.ca. 26 January 2021.
  264. ↑ "A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults". ClinicalTrials.gov. کتابخانه ملی پزشکی ایالات متحده آمریکا. 3 August 2020. NCT04495933. Archived from the original on 11 October 2020. Retrieved 4 August 2020.
  265. ↑ "UQ-CSL V451 Vaccine". precisionvaccinations.com. Archived from the original on 19 December 2020. Retrieved 11 December 2020.
  266. ↑ "Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001) – Full Text View". ClinicalTrials.gov. 30 September 2020. Retrieved 26 January 2021.
  267. ↑ "A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001) – Full Text View". ClinicalTrials.gov. 4 August 2020. Retrieved 26 January 2021.
  268. ↑ "Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates". Merck (Press release). 25 January 2021. Retrieved 25 January 2021.

پیوند به بیرون

ویرایش
برگرفته از «https://fa.wiki.x.io/w/index.php?title=واکسن_کووید-۱۹&oldid=40541135»